Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$0.21 - $0.32 $707 - $1,078
-3,369 Reduced 0.1%
3,367,429 $724,000
Q2 2022

Aug 12, 2022

SELL
$0.26 - $0.64 $2.76 Million - $6.8 Million
-10,619,609 Reduced 75.91%
3,370,798 $880,000
Q1 2022

May 12, 2022

SELL
$0.52 - $1.0 $90,684 - $174,394
-174,394 Reduced 1.23%
13,990,407 $8.39 Million
Q4 2021

Feb 10, 2022

BUY
$0.85 - $1.33 $508,755 - $796,052
598,536 Added 4.41%
14,164,801 $13.9 Million
Q3 2021

Nov 09, 2021

BUY
$1.03 - $1.41 $84,179 - $115,236
81,728 Added 0.61%
13,566,265 $17.6 Million
Q2 2021

Aug 11, 2021

BUY
$1.04 - $1.5 $14 Million - $20.2 Million
13,484,537 New
13,484,537 $14.8 Million

Others Institutions Holding NMTR

About 9 METERS BIOPHARMA, INC.


  • Ticker NMTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,955,400
  • Market Cap $259K
  • Description
  • 9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as we...
More about NMTR
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.